EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Motif Bio revealed there is no pending transaction for iclaprim, the antibiotic that it unsuccessfully tried to bring to market. The biotech is trying to offload the asset as it winds down its business. Release 

> BerGenBio raised NOK 219,875,724 ($23.8 million) to fund clinical trials in acute myeloid leukemia and non-small cell lung cancer. The Norwegian biotech is developing drugs targeting AXL. Statement 

> The U.K. set out its life sciences skills strategy for the coming decade. The report predicts the life sciences sector could create 133,000 jobs over the next 10 years. Release (PDF)

> Autolus raised close to $80 million in a public offering. Statement 

> Hansa Biopharma completed enrollment in a phase 2 trial of imlifidase in a rare immunological disease. The milestone puts Hansa on track to deliver data in the third quarter. Release 

> Khondrion dosed the first patients in a phase 2b trial of sonlicromanol in mitochondrial diseases. The Dutch biotech thinks the drug may improve cognitive function. Statement 

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.